Professor Jacky Smith will current on the correlation between the change in goal cough rely and enchancment in patient-reported outcomes with nalbuphine ER in IPF sufferers

NEW HAVEN, Conn., Sept. 4, 2024 /PRNewswire/ — Trevi Therapeutics (NASDAQ:), Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical firm creating the investigational remedy Haduvio™ (oral nalbuphine ER) for the therapy of power cough in idiopathic pulmonary fibrosis (IPF) and refractory power cough (RCC), right this moment introduced that knowledge from the Part 2a CANAL trial might be introduced on the European Respiratory Society (ERS) Congress 2024 being held in Vienna, Austria from September 7-11. The presentation will happen on September 8^th.

European Respiratory Society (ERS) Congress 2024
September 7-11, 2024, Vienna, Austria
Poster Session: Analysis research in power cough
Session Date & Time: September 8, 8:00 a.m. “ 9:30 a.m. CET
Location: PS-10
Summary Accepted for Oral Presentation: Change in goal cough rely correlates with enchancment in patient-reported outcomes of cough in sufferers with idiopathic pulmonary fibrosis
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medication on the College of Manchester, and an Honorary Advisor at Manchester College NHS Basis Belief. Director of the NIHR Manchester Scientific Analysis Facility, Respiratory Theme Lead within the NIHR Manchester Biomedical Analysis Centre and a NIHR Senior Investigator.

Registration particulars: Registration – ERS Congress – official web site (ersnet.org)

“I am delighted to discuss the correlation between the objective cough monitor and improvements in patient reported outcomes (PRO) with nalbuphine ER. PROs act as an important qualitative data point for clinical trials as they take into consideration the patient perspective. I am excited to present this data from the Phase 2a CANAL trial as treatments for chronic cough continue to be a high unmet need in IPF patients,” stated Prof. Smith.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm creating the investigational remedy Haduvio™ (oral nalbuphine ER) for the therapy of power cough in idiopathic pulmonary fibrosis (IPF) and refractory power cough (RCC). Haduvio is an extended-release (ER) twin ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works each centrally within the mind in addition to peripherally within the lungs and has the potential for a synergistic antitussive impact to deal with power cough. Parenteral nalbuphine just isn’t scheduled by the U.S. Drug Enforcement Company.

The impression of power cough is critical and infrequently results in a decline in sufferers’ social, bodily, and psychological high quality of life. In IPF, power cough might result in worsening illness and could also be related to a better danger of development, dying, or want for lung transplant. There aren’t any accredited therapies for the therapy of power cough in IPF and present therapy choices present minimal profit to sufferers. Persistent cough impacts up to 10% of the grownup inhabitants, and Haduvio’s enlargement into RCC has the potential to succeed in sufferers affected by average to extreme refractory power cough. There are additionally no accredited therapies for RCC within the U.S.

Trevi intends to suggest Haduvio because the commerce identify for oral nalbuphine ER. Its security and efficacy haven’t been evaluated by any regulatory authority.

For extra info, go to www.TreviTherapeutics.com and observe Trevi on X (previously Twitter) and LinkedIn.

Investor Contact
Katie McManusTrevi Therapeutics, Inc.
203-304-2499
okay.mcmanus@trevitherapeutics.com

Media Contact
Rosalia Scampoli914-815-1465
rscampoli@marketcompr.com